VolitionRX Ltd VNRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VNRX is a good fit for your portfolio.
News
-
Volition appoints PharmaVentures for Capture PCR™ and oncology portfolio licensing
-
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
-
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
-
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
-
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
Trading Information
- Previous Close Price
- $0.69
- Day Range
- $0.70–0.77
- 52-Week Range
- $0.55–1.40
- Bid/Ask
- $0.72 / $0.76
- Market Cap
- $62.94 Mil
- Volume/Avg
- 93,959 / 114,666
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 73.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 110
- Website
- https://www.volition.com
Comparables
Valuation
|
Metric
|
VNRX
|
TIHE
|
MRVI
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 162.41 |
Price/Book Value | — | — | 2.96 |
Price/Sales | 73.02 | — | 4.41 |
Price/Cash Flow | — | — | 87.53 |
Price/Earnings
VNRX
TIHE
MRVI
Financial Strength
|
Metric
|
VNRX
|
TIHE
|
MRVI
|
|---|---|---|---|
Quick Ratio | 0.38 | — | 10.19 |
Current Ratio | 0.43 | — | 11.32 |
Interest Coverage | −141.69 | — | 13.71 |
Quick Ratio
VNRX
TIHE
MRVI
Profitability
|
Metric
|
VNRX
|
TIHE
|
MRVI
|
|---|---|---|---|
Return on Assets (Normalized) | −150.74% | — | −0.31% |
Return on Equity (Normalized) | — | — | −1.28% |
Return on Invested Capital (Normalized) | — | — | 0.45% |
Return on Assets
VNRX
TIHE
MRVI
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| Lwrdmjgbn | Rmxx | $226.9 Bil | |||
| Danaher Corp
DHR
| Cwyvmswp | Mwmqwt | $197.8 Bil | |||
| IQVIA Holdings Inc
IQV
| Nvtvbgkgc | Vxcpdm | $43.7 Bil | |||
| Agilent Technologies Inc
A
| Dmrwzldlyr | Wjlw | $39.4 Bil | |||
| IDEXX Laboratories Inc
IDXX
| Zzsdfwjqzt | Wktph | $38.8 Bil | |||
| Mettler-Toledo International Inc
MTD
| Hmwwrzdfx | Cfnnsxk | $30.1 Bil | |||
| Icon PLC
ICLR
| Fdqfmpr | Lnmly | $25.9 Bil | |||
| Illumina Inc
ILMN
| Gjrxxdc | Dwxyzf | $18.7 Bil | |||
| Waters Corp
WAT
| Ybllktwjq | Xckk | $18.4 Bil | |||
| Labcorp Holdings Inc
LH
| Hwtfyhbq | Vqldwp | $17.8 Bil |